Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02188381 · ClinicalTrials.gov registry record
The Role of Gut Microbiota in Hypertension
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 292
- Enrollment target
NCT02188381 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 292 participants.
The verdict
NCT02188381 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 292 participants
- Enrollment target
Study Summary
Hypertension is the single most prevalent risk factor for heart diseases, heart failure, kidney failure and stroke. About 1 in 3 adults in the United States have hypertension. Approximately 28-30% of hypertensive patients suffer from resistant hypertension (RH). Inflammation has been implicated in the pathogenesis of the hypertension. Additional data suggests the involvement of gut microbiota in host normal cardiovascular functions and pathophysiology. Accumulating evidence demonstrates that antibiotic treatment benefits patients with acute coronary syndromes and reduces the incidence of ischemic cardiovascular events. Even though these studies did not address effects of antibiotic treatment on the gut microbiota, it is possible that gut microbiota could affect neurologic inflammation. Finally, intestinal microbiota has recently been proposed to modulate blood pressure (BP) through production of short-chain fatty acids. In order to investigate this, the investigators hypothesize that gut microbiota is involved in the neuroinflammation-mediated initiation and establishment of RH, and targeting gut microbiota by minocycline would produce beneficial outcomes in RH.
Interventions
- OTHER Stool Sample and Blood Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2014-07 |
| Est. Completion | 2020-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02188381
The ClinicalTrials.gov registry entry for NCT02188381 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stool Sample and Blood Sample is the first listed.
NCT02188381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02188381 about?
NCT02188381 is a clinical study titled "The Role of Gut Microbiota in Hypertension". Hypertension is the single most prevalent risk factor for heart diseases, heart failure, kidney failure and stroke. About 1 in 3 adults in the United States have hypertension. Approximately 28-30% of hypertensive patients suffer from resistant hypertension (RH). Inflammation has been implicated in t...
What is the current status of trial NCT02188381?
This trial is currently completed. The enrollment target is 292 participants. The study started on 2014-07. Estimated completion is 2020-08.
What interventions are being tested in trial NCT02188381?
The interventions under investigation include: Stool Sample and Blood Sample (OTHER).
Who is sponsoring clinical trial NCT02188381?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.